|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2B
|
|
pubmed:dateCreated |
2008-5-28
|
|
pubmed:abstractText |
Pegylated liposomal doxorubicin (PLD) is one of the most effective cytotoxic agents in recurrent ovarian cancer. Palmar-plantar erythrodysesthesia (PPE) is a typical and commonly noted adverse event and often represents the dose-limiting toxicity. The purpose of this multicenter study was to determine the efficacy of this regimen as second-line therapy for patients with recurrent ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:Al-BatranSalah-EddinSE,
pubmed-author:ChekerovRadoslavR,
pubmed-author:HindenburgHans-JoachimHJ,
pubmed-author:KlarePeterP,
pubmed-author:KoensgenDominiqueD,
pubmed-author:LichteneggerWernerW,
pubmed-author:NeumannUlfU,
pubmed-author:Oskay-OezcelikGueltenG,
pubmed-author:Ovarian Cancer Study Group of the North-Eastern Germany Society of...,
pubmed-author:SchmalfeldtBarbaraB,
pubmed-author:SehouliJalidJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1329-34
|
|
pubmed:meshHeading |
pubmed-meshheading:18505074-Adult,
pubmed-meshheading:18505074-Aged,
pubmed-meshheading:18505074-Antibiotics, Antineoplastic,
pubmed-meshheading:18505074-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18505074-Doxorubicin,
pubmed-meshheading:18505074-Drug Administration Schedule,
pubmed-meshheading:18505074-Female,
pubmed-meshheading:18505074-Humans,
pubmed-meshheading:18505074-Middle Aged,
pubmed-meshheading:18505074-Organoplatinum Compounds,
pubmed-meshheading:18505074-Ovarian Neoplasms,
pubmed-meshheading:18505074-Paclitaxel,
pubmed-meshheading:18505074-Polyethylene Glycols
|
|
pubmed:articleTitle |
Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
|
|
pubmed:affiliation |
Department of Gynecology and Obstetrics, Charité University Hospital Berlin, Berlin, Germany.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
